A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
Main Authors: | Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749576/ |
Similar Items
-
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
by: Chibaudel, Benoist, et al.
Published: (2016) -
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
by: Chang, T. C., et al.
Published: (2015) -
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko, Andrew H
Published: (2016) -
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
by: Danielle C. Glassman, et al.
Published: (2018-06-01) -
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
by: Chiang, Nai-Jung, et al.
Published: (2016)